FDA and Palantir Partner to Modernize Food Supply Chain Resilience through 21 FORWARD Initiative

DENVER, Oct. 25, 2022 /PRNewswire/ — Palantir Technologies Inc. (NYSE: PLTR) today announced that the Food and Drug Administration (FDA) will expand its work with the company to help modernize the agency’s approach to food supply chain and resilience through the 21 FORWARD Initiative. Palantir will act as the central operating platform for proactive food supply chain disruption monitoring and crisis response. The contract is worth $22 million.

21 FORWARDpowered by the Palantir platform and a part of the FDA’s “New Era of Smarter Food Safety” blueprint, brings together multiple data sources from several government agencies, including the United States Department of Agriculture (USDA) and the Centers for Disease Control and Prevention (CDC), to identify areas of the food supply chain where there will likely be disruptions. The Office of Food Policy and Response (OFPR) leads the 21 FORWARD initiative and was established to implement a modernized approach to food safety for both domestically produced and imported foods.

“Now more than ever public health preparedness is central to our security and safety as a nation and we are honored to support our leading institutions with best in class technology to anticipate and plan for these events,” said Dr. William Kassler, Chief Medical Officer, Palantir. “By leveraging technology, the FDA is investing in a foundational data-driven approach to improve outcomes for our country.”

Launched as a pilot with Palantir in 2020, 21 FORWARD sought to enable users and key stakeholders to dynamically understand and mitigate how domestic COVID-19 incident rates impacted segments of the food system and production — and most recently was leveraged as part of the federal response once infant formula shortage reached a crisis point. The shortage, brought on by the recall of formula, underscored the need for centralization and integration of inter-agency and commercial data sources. Over the past two years and following these two major events, the FDA recognized the real impact a data-driven platform can have and took immediate action to extend this effort. 

21 FORWARD now serves as a coordination hub to support decision-makers with the information they need to respond to similar crises. This contract empowers the FDA to address a broader food safety scope and focus not only on crisis response, but also identify and plan preventative measures in the case of food safety events.

Since partnering with Palantir to support 21 FORWARD, the agency has been able to quickly stand up a scalable infrastructure. With the evolving nature of public health supply chains, it was essential that OFPR have an environment for rapid application configuration. In a matter of weeks, the platform was established as the central operating platform on supply chain analytics related to infant formula earlier this year. 

Additionally, the FDA will leverage investments it has already made in modernized infrastructure and lead with a cloud-first approach. 21 FORWARD is deployed in the Palantir Federal Cloud Service (PFCS), Palantir Technologies’ FedRAMP Moderate cloud environment. The initiative’s hosting infrastructure and operations are a managed, standardized, tested, and externally audited Software-as-a-Service (SaaS) platform that scales to meet demand. Palantir is certified compliant with the following industry standards and frameworks to provide the highest levels of security to the FDA, including: SOC 2 Type 2 (Security, Confidentiality, and Availability), FedRAMP (Moderate), and IL6 DoD SRG. 

Palantir has deep experience in the public and commercial health sectors and is a proven leader in delivering mission critical software across the public health supply chain.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Media Contact 

Lisa Gordon, media@palantir.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-and-palantir-partner-to-modernize-food-supply-chain-resilience-through-21-forward-initiative-301657536.html



Source link

The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy